Purple Biotech (XTAE:PPBT) ROCE % : -52.79% (As of Dec. 2023)

View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Purple Biotech's annualized ROCE % for the quarter that ended in Dec. 2023 was -52.79%.

Purple Biotech ROCE % Historical Data

The historical data trend for Purple Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech ROCE % Chart

Purple Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-45.27

-62.36

-24.20

-38.22

-47.05

Purple Biotech Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-48.59	-40.78	-44.26	-49.06	-52.79

Purple Biotech ROCE % Calculation

Purple Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-75.787	/	( ( (207.804 - 26.851)	+	(168.542 - 27.327) )	/ 2 )
	=	-75.787	/	( (180.953	+	141.215)	/ 2 )
	=	-75.787	/	161.084
	=	-47.05 %

Purple Biotech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-76.484	/	( ( (172.233 - 23.663)	+	(168.542 - 27.327) )	/ 2 )
	=	-76.484	/	( ( 148.57	+	141.215 )	/ 2 )
	=	-76.484	/	144.8925
	=	-52.79 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Purple Biotech (XTAE:PPBT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Purple Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Purple Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech (XTAE:PPBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PPBT:USA 1YI1:Germany

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.